colchicine has been researched along with Atherogenesis in 52 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.92) | 29.6817 |
| 2010's | 15 (28.85) | 24.3611 |
| 2020's | 36 (69.23) | 2.80 |
| Authors | Studies |
|---|---|
| Alataki, S; Douma, S; Koletsos, N; Papadopoulou-Alataki, E; Papadopoulou-Legbelou, K; Triantafyllou, A; Vampertzi, O | 1 |
| Franczyk, B; Gluba-Brzózka, A; Rysz, J; Rysz-Górzyńska, M; Ławiński, J | 1 |
| Fontes-Carvalho, R; Vilela, EM | 1 |
| Doulamis, IP; Iliopoulos, DC; Kaminiotis, VV; Kapelouzou, A; Kontogiannis, C; Mastrogeorgiou, M; Mylonas, KS; Nikiteas, N; Siasos, G; Spartalis, E; Spartalis, M; Toutouzas, K | 1 |
| Agnello, F; Capodanno, D | 1 |
| Cuciuc, V; George, J; Haberman, D; Sella, G; Tuvali, O | 1 |
| Anastasiou, A; Iliopoulos, DC; Siasos, G; Spartalis, E; Spartalis, M; Tzima, I | 1 |
| Layland, J; Nidorf, SM; Patel, S; Psaltis, PJ; Robinson, PC; Thompson, PL | 1 |
| Abu Fanne, R; Arbel, Y; Banai, S; Chorin, E; Groisman, GM; Higazi, AA; Maraga, E | 1 |
| Johansen, NJ; Knop, FK | 1 |
| Bursill, CA; Chen, YC; Dimasi, C; Eddy, E; Fernando, S; Kanellakis, P; Liyanage, S; Manavis, J; Nicholls, SJ; Peter, K; Psaltis, PJ; Rao, SR; Salagaras, T; Sargeant, TJ; Schwarz, N; Snel, MF; Tan, JTM; Thompson, PL; Toledo-Flores, D; Williamson, AE | 1 |
| Aquilani, S; Caldarola, P; Colivicchi, F; De Luca, L; Di Fusco, SA; Gabrielli, D; Gatto, L; Gulizia, MM; Imazio, M; Nardi, F; Oliva, F; Riccio, C; Rizzello, V; Spinelli, A | 1 |
| Nidorf, SM | 1 |
| Fuster, V; Nelson, K; Ridker, PM | 1 |
| Bax, WA; Cornel, JH; El Messaoudi, S; Mohammadnia, N; Opstal, TSJ | 1 |
| Chen, Q; Li, T; Su, Z; Tang, J; Xiong, X; Yang, Q; Zheng, M | 1 |
| Douma, S; Papadopoulou-Alataki, E; Papadopoulou-Legbelou, K; Triantafyllou, A; Vampertzi, O | 1 |
| Bax, WA; Budgeon, CA; Cornel, JH; Eikelboom, JW; Fiolet, ATL; Mosterd, A; Nidorf, SM; Opstal, TSJ; Schut, A; Thompson, PL; Tijssen, JGP | 1 |
| Blumenthal, RS; Gulati, M; Mahtta, D; Mehta, A; Sperling, LS; Virani, SS | 1 |
| Ridker, PM | 1 |
| Abdeen, S; Abu-Fanne, R; Bdeir, K; Cines, DB; Heyman, SN; Higazi, AA; Higazi, M; Maraga, E; Masarwy, A | 1 |
| Barbas, C; Cecconi, A; Godzien, J; Ibañez, B; Izidoro, MA; López-Gonzálvez, Á; Mateo, J; Panadero, MI; Ruiz-Cabello, J; Rupérez, FJ; Vilchez, JP | 1 |
| Hernandez, AV; Roman, YM; White, CM | 1 |
| Camici, GG; Liberale, L; Lüscher, TF; Montecucco, F; Schwarz, L | 1 |
| Butt, AK; Cave, B; Khouzam, RN; Maturana, M; Towers, WF | 1 |
| Aimo, A; Barison, A; Bayes-Genis, A; Cediel, G; Emdin, M; Pascual-Figal, DA; Saccaro, LF; Vicente, ÁH | 1 |
| Figtree, G; Galougahi, KK; Kurup, R; Misra, A; Patel, S | 1 |
| Blondeau, L; Bouabdallaoui, N; Tardif, JC | 1 |
| Samuel, M; Tardif, JC | 1 |
| Arcudi, A; Borovac, JA; Cappannoli, L; Cappetta, D; Chouchane, K; Crea, F; D'Amario, D; De Angelis, A; Diana, G; Galli, M; Liuzzo, G; Migliaro, S; Montone, RA; Princi, G; Restivo, A; Vergallo, R | 1 |
| Katira, A; Katira, R | 1 |
| Açarı, C; Dundar, HA; Kır, M; Küme, T; Makay, B; Türkuçar, S; Ünsal, E; Yıldız, K | 1 |
| Banach, M; Penson, PE | 1 |
| Bakoyiannis, C; Iliopoulos, D; Kapelouzou, A; Liakakos, T; Mastrogeorgiou, M; Mylonas, KS; Nikiteas, N; Schizas, D; Spartalis, E; Spartalis, M | 1 |
| Bouabdallaoui, N; Tardif, JC | 1 |
| Li, Y; Lu, J; Xie, J; Xu, B; Yin, Y; Zhang, Y | 1 |
| Marquis-Gravel, G; Tardif, JC | 1 |
| Agrogiannis, G; Androutsopoulou, V; Dontas, IA; Iliopoulos, DC; Kaminiotis, VV; Konstantopoulos, P; Korou, LM; Perrea, D; Vlachos, IS | 1 |
| Deftereos, S; Giannopoulos, G; Jatuzis, D; Katsanos, AH; Kelly, PJ; Lemmens, R; Panagopoulou, V; Tsivgoulis, G | 1 |
| Celermajer, DS; Martínez, GJ; Patel, S | 2 |
| Chistiakov, DA; Grechko, AV; Melnichenko, AA; Myasoedova, VA; Orekhov, AN | 1 |
| Hoss, F; Latz, E | 1 |
| Martínez, G; Patel, S; Vaidya, K | 1 |
| Nidorf, SM; Thompson, PL | 2 |
| Chatzidou, S; Iliopoulos, DC; Kaminiotis, VV; Kontogiannis, C; Moris, D; Paschou, SA; Siasos, G; Spartalis, E; Spartalis, M; Tsilimigras, DI; Tzatzaki, E; Voudris, V | 1 |
| Schulz, C; Stark, K; Stremmel, C | 1 |
| Lüscher, TF; Ridker, PM | 1 |
| Bäck, M; Hansson, GK | 1 |
| Abd-Elrahman, I; Abdeen, S; Abu-Fanne, R; Blum, G; Cines, DB; Hankin, A; Higazi, AA; Hijazi, N; Maraga, E | 1 |
| Akar, S; Akkoc, N; Birlik, M; Can, G; Goktay, Y; Gulcu, A; Karaoglu, O; Onen, F; Sari, I; Tunca, M | 1 |
28 review(s) available for colchicine and Atherogenesis
| Article | Year |
|---|---|
Emerging Anti-Atherosclerotic Therapies.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Atherosclerosis; Cardiovascular Diseases; Colchicine; Humans; Immunity, Innate; Inflammation; Interleukin-1beta; P-Selectin; p38 Mitogen-Activated Protein Kinases; Risk Factors | 2021 |
Inflammation and ischemic heart disease: The next therapeutic target?
Topics: Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Humans; Inflammation; Myocardial Ischemia | 2021 |
Colchicine in Atherosclerotic Vascular Disease: The Good, the Bad, and the Ugly.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Humans | 2022 |
Seeing Colchicine in a New Light: Repurposing Low-dose Colchicine for Secondary Prevention of Cardiovascular Disease.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Cardiovascular Diseases; Colchicine; Coronary Artery Disease; Drug Repositioning; Gout; Humans; Secondary Prevention; Symptom Flare Up | 2023 |
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week.
Topics: Adult; Atherosclerosis; Cholesterol, LDL; Colchicine; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Myocardial Infarction; Secondary Prevention | 2023 |
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Biomarkers; Colchicine; Humans; Inflammasomes; Inflammation; Lipids | 2023 |
Familial Mediterranean fever and atherosclerosis in childhood and adolescence.
Topics: Adolescent; Albuminuria; Asymptomatic Diseases; Atherosclerosis; Carotid Intima-Media Thickness; Child; Cholesterol, HDL; Colchicine; Echocardiography; Endothelium, Vascular; Familial Mediterranean Fever; Humans; Inflammation; Neoplasm Proteins; Proteoglycans; Pulse Wave Analysis; Stroke Volume; Triglycerides; Tubulin Modulators | 2020 |
Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions.
Topics: American Heart Association; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Colchicine; Eicosapentaenoic Acid; Humans; Interleukin-6; Mutation; Myocardial Infarction; PCSK9 Inhibitors; Receptors, Interleukin-6; Risk Factors; United States | 2020 |
The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Colchicine; Female; Humans; Immunity, Innate; Inflammation; Male; Methotrexate; Middle Aged; Treatment Outcome | 2020 |
Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Atherosclerosis; Colchicine; Evidence-Based Medicine; Humans; Inflammation; Inflammation Mediators; Randomized Controlled Trials as Topic; Research Design; Signal Transduction; Thrombosis; Treatment Outcome | 2021 |
The Role of Colchicine in Coronary Artery Disease.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Clinical Trials, Phase III as Topic; Colchicine; Coronary Artery Disease; Humans; Plaque, Atherosclerotic; Randomized Controlled Trials as Topic | 2021 |
Colchicine for the treatment of coronary artery disease.
Topics: Acute Coronary Syndrome; Atherosclerosis; Colchicine; Coronary Artery Disease; Humans; Myocardial Infarction | 2021 |
The Role of Colchicine in Atherosclerotic Cardiovascular Disease.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Cardiovascular Diseases; Colchicine; Coronary Artery Disease; Humans; Plaque, Atherosclerotic | 2021 |
Colchicine in ischemic heart disease: the good, the bad and the ugly.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Coronary Artery Disease; Humans; Inflammation; Myocardial Ischemia; Plaque, Atherosclerotic; Randomized Controlled Trials as Topic | 2021 |
Colchicine in coronary artery disease.
Topics: Acute Coronary Syndrome; Atherosclerosis; Colchicine; Coronary Artery Disease; Humans; Myocardial Infarction | 2022 |
Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Coronary Artery Disease; Humans | 2021 |
Colchicine in the Management of Acute and Chronic Coronary Artery Disease.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Coronary Artery Disease; Humans; Myocardial Infarction | 2021 |
Anti-inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Humans; Inflammasomes; Inflammation; NLR Family, Pyrin Domain-Containing 3 Protein; Plaque, Atherosclerotic | 2021 |
The Role of Colchicine in the Prevention of Cerebrovascular Ischemia.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Brain Ischemia; Colchicine; Gout Suppressants; Humans; Inflammation | 2018 |
The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.
Topics: Animals; Anti-Inflammatory Agents; Arteries; Atherosclerosis; Colchicine; Cytokines; Humans; Inflammasomes; Inflammation; Inflammation Mediators; Macrophages; Monocytes; Neutrophils; NLR Family, Pyrin Domain-Containing 3 Protein; Plaque, Atherosclerotic; Signal Transduction | 2018 |
Potential of anti-inflammatory agents for treatment of atherosclerosis.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Colchicine; Cyclooxygenase 2 Inhibitors; Cytokines; Humans; Inflammation; Leukotrienes; Methotrexate; Molecular Targeted Therapy; Phospholipase A2 Inhibitors; Signal Transduction | 2018 |
The Role of Colchicine in Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Coronary Artery Disease; Cytokines; Humans; Inflammation; Monocytes | 2019 |
Colchicine: an affordable anti-inflammatory agent for atherosclerosis.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Costs and Cost Analysis; Humans | 2018 |
The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.
Topics: Acute Coronary Syndrome; Animals; Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Coronary Artery Disease; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Inflammation; Myocardial Infarction; Plaque, Atherosclerotic | 2018 |
Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Coronary Artery Disease; Cytokines; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1beta; Secondary Prevention | 2019 |
Heterogeneity of Macrophages in Atherosclerosis.
Topics: Animals; Atherosclerosis; Cell Adhesion; Colchicine; Humans; Immune System; Inflammation; Lipoproteins, LDL; Macrophages; Mice; Monocytes; Phagocytosis; Phenotype; Treatment Outcome | 2019 |
Anti-inflammatory therapies for cardiovascular disease.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; C-Reactive Protein; Carrier Proteins; Cell Adhesion Molecules; Colchicine; Humans; Hydroxychloroquine; Interleukin-1; Interleukin-6; Leukotriene Antagonists; Lipoproteins, HDL; Methotrexate; NLR Family, Pyrin Domain-Containing 3 Protein; Phospholipase A2 Inhibitors; Receptors, Interleukin-1; Serpins; Signal Transduction; Sirtuins; Thrombosis; Tumor Necrosis Factor-alpha; Vaccination | 2014 |
Anti-inflammatory therapies for atherosclerosis.
Topics: Allopurinol; Anti-Inflammatory Agents; Atherosclerosis; Biological Products; Colchicine; Humans; Methotrexate; Phospholipases; Signal Transduction; Tumor Necrosis Factor-alpha; Vaccination | 2015 |
1 trial(s) available for colchicine and Atherogenesis
| Article | Year |
|---|---|
The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Australia; Cardiovascular Diseases; Clinical Trial Protocols as Topic; Colchicine; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Repositioning; Female; Humans; Male; Middle Aged; Myocardial Infarction; Netherlands; Percutaneous Coronary Intervention; Secondary Prevention; Stroke; Tubulin Modulators | 2019 |
23 other study(ies) available for colchicine and Atherogenesis
| Article | Year |
|---|---|
Assessment of vascular damage in children and young adults with Familial Mediterranean Fever.
Topics: Adolescent; Adult; Atherosclerosis; Biomarkers; Case-Control Studies; Child; Child, Preschool; Colchicine; Cross-Sectional Studies; Familial Mediterranean Fever; Female; Humans; Male; Mutation; Severity of Illness Index; Tubulin Modulators; Young Adult | 2022 |
The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits.
Topics: Acetylcysteine; Administration, Oral; Animals; Anti-Inflammatory Agents; Aorta; Atherosclerosis; C-Reactive Protein; Cholesterol; Colchicine; Drug Therapy, Combination; Fenofibrate; Hypolipidemic Agents; Interleukin-6; Male; NLR Family, Pyrin Domain-Containing 3 Protein; Rabbits; Triglycerides | 2021 |
Anti-inflammatory strategies for atherosclerotic artery disease.
Topics: Anti-Inflammatory Agents; Arteries; Atherosclerosis; Colchicine; Coronary Artery Disease; Humans; Inflammation | 2022 |
Anti-inflammatory Drug Combination Therapy for Atherosclerosis:\
Colchicine and Fenofibrate
Topics: Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Coronary Artery Disease; Drug Combinations; Fenofibrate; Humans | 2022 |
Emerging evidence for the use of colchicine for secondary prevention of coronary heart disease.
Topics: Atherosclerosis; Colchicine; Coronary Artery Disease; Humans; Secondary Prevention | 2022 |
Association between tissue human neutrophil peptide 1-3 levels and cardiovascular phenotype: a prospective, longitudinal cohort study.
Topics: alpha-Defensins; Atherosclerosis; Cohort Studies; Colchicine; Coronary Artery Disease; Humans; Longitudinal Studies; Phenotype; Plaque, Atherosclerotic; Prospective Studies; Risk Factors | 2022 |
The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes.
Topics: Atherosclerosis; Brain Ischemia; Colchicine; Diabetes Mellitus, Type 1; Humans; Inflammation; Stroke | 2023 |
Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Carotid Stenosis; Cholesterol; Colchicine; Foam Cells; Humans; Mice | 2023 |
[ANMCO Position paper: Colchicine as a therapeutic agent in coronary syndromes].
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Humans; Inflammation | 2023 |
Colchicine delivered by a novel nanoparticle platform alleviates atherosclerosis by targeted inhibition of NF-κB/NLRP3 pathways in inflammatory endothelial cells.
Topics: Animals; Atherosclerosis; Colchicine; Endothelial Cells; Inflammation; Mice; Nanoparticles; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Plaque, Atherosclerotic | 2023 |
From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; C-Reactive Protein; Colchicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1beta; Interleukin-6; Lipid Metabolism; Methotrexate; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction | 2020 |
Opposing effects of HNP1 (α-defensin-1) on plasma cholesterol and atherogenesis.
Topics: alpha-Defensins; Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Cholesterol; Cholestyramine Resin; Colchicine; Diet, High-Fat; Disease Models, Animal; Female; Humans; Lipid Metabolism; Lipoproteins, LDL; Mice; Mice, Knockout, ApoE; Mice, Transgenic; Neutrophils | 2020 |
Plasma Metabolic Signature of Atherosclerosis Progression and Colchicine Treatment in Rabbits.
Topics: Animals; Atherosclerosis; Colchicine; Dietary Fats; Disease Models, Animal; Disease Progression; Humans; Metabolomics; Rabbits; Random Allocation | 2020 |
Lessons from COLCOT and LoDoCo2: colchicine for secondary prevention in coronary artery disease.
Topics: Atherosclerosis; Colchicine; Coronary Artery Disease; Humans; Myocardial Infarction; Secondary Prevention | 2021 |
Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2).
Topics: Atherosclerosis; Cardiovascular Diseases; Colchicine; Humans; Inflammation | 2021 |
Does Familial Mediterranean Fever Provoke Atherosclerosis in Children? Evaluation of Arterial Stiffness and Serum Endocan Levels.
Topics: Adolescent; Adult; Atherosclerosis; Case-Control Studies; Child; Colchicine; Endothelial Cells; Familial Mediterranean Fever; Humans; Pyrin; Vascular Stiffness | 2021 |
KLF4 Upregulation in Atherosclerotic Thoracic Aortas: Exploring the Protective Effect of Colchicine-based Regimens in a Hyperlipidemic Rabbit Model.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Colchicine; Disease Models, Animal; Drug Therapy, Combination; Fibric Acids; Hyperlipidemias; Kruppel-Like Factor 4; Male; Plaque, Atherosclerotic; Rabbits; Up-Regulation | 2022 |
Low-Dose Colchicine for the Management of Coronary Artery Disease.
Topics: Atherosclerosis; Colchicine; Coronary Artery Disease; Humans; Myocardial Infarction | 2021 |
Per os colchicine administration in cholesterol fed rabbits: Triglycerides lowering effects without affecting atherosclerosis progress.
Topics: Administration, Oral; Animals; Aorta; Atherosclerosis; Blood Glucose; Cholesterol, Dietary; Colchicine; Insulin; Interleukin-18; Leptin; Lipid Metabolism; Male; Rabbits; Triglycerides; Tunica Intima | 2017 |
Inhibitory effects of colchicine on inflammasomes.
Topics: Atherosclerosis; Colchicine; Humans; Inflammasomes; Inflammation; NLR Family, Pyrin Domain-Containing 3 Protein | 2018 |
Reply to: "Inhibitory effects of colchicine on inflammasomes".
Topics: Atherosclerosis; Colchicine; Humans; Inflammasomes; Inflammation; NLR Family, Pyrin Domain-Containing 3 Protein | 2018 |
α-Defensins Induce a Post-translational Modification of Low Density Lipoprotein (LDL) That Promotes Atherosclerosis at Normal Levels of Plasma Cholesterol.
Topics: alpha-Defensins; Animals; Atherosclerosis; Cathepsins; Cholesterol; Colchicine; Endothelial Cells; Humans; Inflammation; Lipoproteins, LDL; Male; Mice; Mice, Transgenic; Multiprotein Complexes; Protein Processing, Post-Translational | 2016 |
Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever.
Topics: Adolescent; Adult; Atherosclerosis; Biomarkers; Brachial Artery; Carotid Artery Diseases; Carotid Artery, Common; Case-Control Studies; Colchicine; Familial Mediterranean Fever; Female; Humans; Male; Tunica Intima; Ultrasonography | 2007 |